Pilot to validate in vivo 2-HG MR spectroscopy in low grade gliomas
- Conditions
- 2-HGMRISpectroscopyLow grade gliomaIDH
- Registration Number
- NL-OMON24067
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other
- Sex
- Not specified
- Target Recruitment
- 10
Inclusion Criteria
Patients with a low grade glioma ≥ 18 years that are planned to undergo surgery
Exclusion Criteria
- Patients with recent cerebral radiotherapy or operation (<3 months).
- Age <18 years.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary endpoint is the correlation between the presence of the IDH mutation and a 2-HG peak on MR spectroscopy (binary variables). Also primary endpoint is the correlation between the concentration of 2-HG on in vivo MR spectroscopy and ex vivo in the tissue, uitgedrukt in mmol/mg (continue variabelen).
- Secondary Outcome Measures
Name Time Method not applicable